David Kabakoff

David Kabakoff joined Sofinnova Ventures as an Executive Partner in 2007, and also serves as a partner in HealthQuest Capital. Dr. Kabakoff has more than 30 years of experience leading technology and product development programs in the pharmaceutical, biopharmaceutical, diagnostics, and drug delivery fields. He served as Chairman of Trius Therapeutics (acquired by Cubist), Chairman of Amplimmune (acquired by Astra Zeneca), as a Director of InterMune, Inc. (acquired by Roche), and Director of Allylix, Inc. (acquired by Evolva). Dr. Kabakoff also served as a Board Observer at Intellikine (acquired by Takeda).  He currently serves as the Chairman of the Board of Lineagen and as an Observer to the Board of Castle BioSciences and of Histogenics.

Dr. Kabakoff co-founded Salmedix, Inc., a developer of cancer drugs, and served as Chairman and Chief Executive Officer (acquired by Cephalon Inc.).  Dr. Kabakoff also held the positions of Executive Vice President of Dura, a specialty respiratory pharmaceutical and pulmonary drug delivery company, and President and Chief Executive Officer of Spiros Development Corp. Prior to Dura, Dr. Kabakoff was Chief Executive Officer of Corvas International and held senior executive positions with Hybritech, Inc.

Dr. Kabakoff received his Ph.D. from Yale University and his B.A. from Case Western Reserve University.